Efficient Delivery of Oncolytic Peptide LTX-315 by ZIF-8: pH-Responsive Release, Improved Stability, and Reduced Hemolysis.

Chen XQ, Cui SS, Chen YZ, Wang CY, Liu Q, Qi YK, Du SS

Molecular pharmaceutics6 Feb 2025Cited by 3 (Europe PMC)

PMID39913295DOI10.1021/acs.molpharmaceut.4c01144PepBankPUB-39913295

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking LTX-315.

01LabNot a test of LTX-315 aloneIn vitro (cells)Efficacy outcome
In cancer cells, LTX‑315@ZIF-8 nanoparticles exhibited potent cytotoxicity.
In plain wordsIn cells, LTX‑315 nanoparticles showed potent cancer cell toxicity.
Peptide
LTX-315
Outcome
IncreaseCancer cell cytotoxicity
Study
n: not reported in source
Cancer cells
Outcome group
Tumor growth · Cancer
Source sentences
Summary
LTX-315@ZIF-8 NPs exhibited potent cytotoxicity against cancer cells.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-3991329501
02LabNot a test of LTX-315 aloneIn vitro (cells)Efficacy outcome
In time-inhibition assays, ZIF-8 nanoparticles prolonged LTX‑315 anticancer action.
In plain wordsIn lab tests, nanoparticles prolonged LTX‑315 anticancer action.
Peptide
LTX-315
Outcome
IncreaseAnticancer action duration
Study
n: not reported in source
Cancer cells
Outcome group
Tumor growth · Cancer
Source sentences
Summary
The serum stability experiment and time-inhibition curve assay indicated that ZIF-8 NPs could effectively improve the stability of LTX-315, prolong the duration of anticancer action, and enhance the cytostatic potency.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-3991329503
03LabNot a test of LTX-315 aloneIn vitro (cells)Efficacy outcome
In time-inhibition assays, ZIF-8 nanoparticles enhanced LTX‑315 cytostatic potency.
In plain wordsIn cells, nanoparticles enhanced LTX‑315 growth inhibition.
Peptide
LTX-315
Outcome
IncreaseCytostatic potency
Study
n: not reported in source
Cancer cells
Outcome group
Tumor growth · Cancer
Source sentences
Summary
The serum stability experiment and time-inhibition curve assay indicated that ZIF-8 NPs could effectively improve the stability of LTX-315, prolong the duration of anticancer action, and enhance the cytostatic potency.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-3991329504
04LabNot a test of LTX-315 aloneIn vitro (cells)Safety outcome
In laboratory tests, LTX‑315@ZIF-8 nanoparticles attenuated LTX‑315 hemolytic toxicity.
In plain wordsIn lab tests, nanoparticles reduced LTX‑315 toxicity to red blood cells.
Peptide
LTX-315
Outcome
DecreaseHemolytic toxicity
Study
n: not reported in source
Red blood cells
Outcome group
Adverse events · Cancer
Source sentences
Summary
Especially, the LTX-315@ZIF-8 NPs not only effectively attenuated the hemolytic toxicity of LTX-315 but also achieved the pH-responsive release of LTX-315.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-3991329505
05LabNot a test of LTX-315 aloneIn vitro (cells)Mechanism
In laboratory tests, LTX‑315@ZIF-8 nanoparticles possessed potent membranolytic activity.
In plain wordsIn lab tests, LTX‑315 nanoparticles disrupted membranes.
Peptide
LTX-315
Outcome
Not applicableMembranolytic activity
Study
n: not reported in source
Cancer cells
Outcome group
Receptor activity and mechanism · Cancer
Source sentences
Summary
The mechanism investigation indicated that LTX-315@ZIF-8 NPs possessed potent membranolytic activity and reduced the mitochondrial membrane potential to trigger cell death.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-3991329507
06LabNot a test of LTX-315 aloneIn vitro (cells)Mechanism
In laboratory tests, LTX‑315@ZIF-8 nanoparticles reduced mitochondrial membrane potential to trigger cell death.
In plain wordsIn cells, LTX‑315 nanoparticles reduced mitochondrial membrane potential to trigger cell death.
Peptide
LTX-315
Outcome
DecreaseMitochondrial membrane potential
Study
n: not reported in source
Cancer cells
Outcome group
Mitochondrial function · Cancer
Source sentences
Summary
The mechanism investigation indicated that LTX-315@ZIF-8 NPs possessed potent membranolytic activity and reduced the mitochondrial membrane potential to trigger cell death.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-3991329508
07LabNot a test of LTX-315 aloneIn vitro (cell-free)Pharmacokinetics
In serum stability tests, ZIF-8 nanoparticles improved LTX‑315 stability.
In plain wordsIn lab tests, nanoparticles improved LTX‑315 stability.
Peptide
LTX-315
Outcome
IncreaseSerum stability
Study
n: not reported in source
Serum stability assay
Outcome group
Pharmacokinetics · Cancer
Source sentences
Summary
The serum stability experiment and time-inhibition curve assay indicated that ZIF-8 NPs could effectively improve the stability of LTX-315, prolong the duration of anticancer action, and enhance the cytostatic potency.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-3991329502
08LabNot a test of LTX-315 aloneIn vitro (cell-free)Pharmacokinetics
In laboratory tests, LTX‑315@ZIF-8 nanoparticles achieved pH-responsive peptide release.
In plain wordsIn lab tests, nanoparticles released LTX‑315 in response to pH.
Peptide
LTX-315
Outcome
Not applicablepH-responsive release
Study
n: not reported in source
Nanoparticle release assay
Outcome group
Pharmacokinetics · Cancer
Source sentences
Summary
Especially, the LTX-315@ZIF-8 NPs not only effectively attenuated the hemolytic toxicity of LTX-315 but also achieved the pH-responsive release of LTX-315.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-3991329506

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
27 Oct 2026, 18:20 UTC
Study results updated
Version 1
27 Oct 2026, 16:32 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.